New kidney drug tested in patients with liver issues
NCT ID NCT06674915
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study looked at how the drug HRS-5965 behaves in people with mild or moderate liver impairment compared to those with normal liver function. Twenty-four adults took a single 50 mg dose of the drug. The goal was to measure drug levels in the blood and check for side effects, not to treat the kidney disease itself.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-5965
What this could lead to
If successful, this study could help determine safe dosing of HRS-5965 for people with liver problems, potentially leading to better treatment options for kidney diseases.
What could go wrong
This is an early Phase 1 study with only 24 people, focused on safety and drug levels, not on treating the disease. Results may not predict effectiveness or apply to broader populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Suzhou University
Suzhou, Jiangsu, 215008, China